Strengthening the Stable Supply System and Quality through Group Collaboration
First written in FY2017. 1 of 3 entries say "Advanced", first in FY2021. Latest entry: FY2022.
15 other companies' latest entry also says "Restated".
- FY2022RestatedAnnual report
「Regarding stable product supply, no significant events have occurred in the supply chain for active pharmaceutical ingredients and finished products, and we maintain sufficient inventories of raw materials and products, among other items, enabling us to maintain a system for stable supply.」
Continues to explain that the stable supply system is being maintained through sufficient inventories, with no significant supply chain events. - FY2021AdvancedAnnual report
「Regarding stable product supply, no significant events have occurred in the supply chain for active pharmaceutical ingredients and finished products, and we maintain sufficient inventories of raw materials and products, among other items, enabling us to maintain a system for stable supply.」
Specifically describes the absence of significant events in the supply chain for active pharmaceutical ingredients and finished products, sufficient inventories and the maintenance of a stable supply system. - FY2017First statedAnnual report
「Expanding the stable supply system and further improving quality by strengthening collaboration across the Group」
For the first time, explicitly identifies strengthening the stable supply system and quality of pharmaceuticals through collaboration across the Group as an issue to address.